$DVLT

Mbugua Stanley sold $26K of DVLT

Mbugua Stanley (See Remarks) sold 62,982 shares of Datavault AI Inc. (DVLT) at $0.41 on 2026-06-10.

Original reporting
SEC EDGAR · Mbugua Stanley
Published Jun 12, 2026, 8:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DVLT
Neutral
medium confidence
Mentioned
$DVLT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVLTNeutralLow
01

Why it matters

The newest fact is the specific open-market sale quantity, price, and post-transaction holdings by an officer, which may marginally affect sentiment but does not change company fundamentals.

02

Market read

A modest officer sale was disclosed; traders may treat it as a minor sentiment datapoint rather than a catalyst.

03

What to watch

The filing doesn’t disclose reasons for sale, tax/option exercises, or whether other insiders are buying; monitor for clustering of additional Form 4 sales.

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-12; sale executed 2026-06-10.

Background

The article is an SEC Form 4 insider transaction disclosure for Datavault AI Inc. (DVLT).

Company-level read

Ticker impact

$DVLTNeutralMedium confidence
Context

Officer Mbugua Stanley filed an open-market sale of 62,982 DVLT shares on 2026-06-10 for ~$25.6K, per Form 4.

Expected impact

Low near-term impact; any effect is likely sentiment-only unless follow-on selling accelerates.

Evidence & confidence

This is a Form 4 insider transaction (primary-source) but the transaction size (~$25.6K) is modest and the filing provides no new company fundamentals.

Market effects

Minimal; single-company insider sale without accompanying operational/regulatory updates.

None indicated.

None indicated.

Counterpoint

Insider sales can be pre-planned for liquidity needs; the absence of a 10b5-1 plan doesn’t necessarily imply negative fundamentals.

Key entities

  • Datavault AI Inc.

    Subject of the Form 4 insider sale disclosure (DVLT).

  • Mbugua Stanley

    Officer who sold 62,982 shares in an open-market transaction.

Related articles

$DVLTMed

Datavault AI Hit With Securities Lawsuit

Datavault AI Inc. (NASDAQ: DVLT) faces a new securities class action, according to DJS Law Group, alleging the company misled investors about operations, partnerships, and growth prospects. The proposed class period is Sept. 4, 2024 to Oct. 30, 2025. The claims stem largely from a Wolfpack Research report that preceded a ~19% one-day share drop. Lead plaintiff deadline is Oct. 5, 2026.

$DVLTMed

Pomerantz Law Firm Announces the Filing of a Class Action Against Datavault AI Inc. and Certain Officers - DVLT

Pomerantz LLP said it filed a securities class action against Datavault AI Inc. (NASDAQ: DVLT) and certain officers in the Eastern District of Pennsylvania, covering purchases from Sept. 4, 2024 to Oct. 30, 2025. The suit alleges misleading statements about partnerships, trading activity, and compliance. After a Wolfpack Research report on Oct. 31, 2025, DVLT shares fell 19.44% to $2.03.

$DVLTMed

Datavault AI Expands Data Driven Outcome Healthcare

Datavault AI (NASDAQ:DVLT) said it amended its definitive agreement with DataMeds AI (NASDAQ:MEDS) to expand a PharmacyChain blockchain technology licensing relationship into unencumbered commercial healthcare, healthspan and wellness uses. Datavault AI will receive common shares worth about 19.9% of DataMeds’ stock at closing, replacing preferred shares for tax optimization.

$MEDSMed

DataMEDS AI, Inc.: DataMeds AI Expands License with DataVault AI for Data Driven Outcome Healthcare-focused Blockchain and Data Monetization License

DataMeds AI (NASDAQ:MEDS) said it amended its licensing agreement with Datavault AI (NASDAQ:DVLT) to expand PharmacyChain blockchain-related licensing from pharmaceutical distribution to all unencumbered commercial healthcare, healthspan and wellness uses. The deal is tied to a pending multi-party combination and includes DVLT receiving common shares worth about 19.9% of MEDS at closing.